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An economical biomanufacturing paradigm for human mesenchymal stem/stromal cells (hMSCs) is in critical 
need, as indicated by over 800 clinical trials investigating the use of hMSCs for regenerative medicine. To meet 
the demand for clinical manufacturing, a scalable process and production technology platform that can generate 
billions to trillions of cells per manufacturing lot is needed. Suspension bioreactors show great promise in 
reaching commercially-viable working volumes, however, scalability of cell production remains an issue. 
Overcoming this challenge is necessary to drive widespread adoption of this culture system for hMSCs. We 
have taken the Quality by Design (QbD) approach to develop a scalable xeno-free (XF) hMSC bioreactor 
process that maintains the final cell population doubling level (PDL) within the recommended range of 16-20 to 
ensure product quality. Our strategic XF bioprocess was designed using high volume XF cell banks, an 
optimized XF fed-batch media system, and XF microcarriers, all combined in a scalable bioreactor system to 
meet our design criteria and streamlined production at different culture scales.  
 
In this study, we demonstrated the scalability of a XF hBM-MSC microcarrier suspension culture in a low shear, 
single-use, vertical-wheel suspension bioreactor (PBS Biotech) at small scale (0.1 L), development scale (3 L), 
and pilot scale (15 L). Cell yields of >0.5M cells/mL were achieved in all bioreactor scales within 5 days of 
culture with no media exchange. Comparable nutrient and waste metabolite levels, pH, and cell growth curves 
(Fig. 1) were observed at each scale. In addition, cells harvested from all bioreactor scales maintain the hMSC 
critical quality attributes of osteogenic, adipogenic, and chondrogenic differentiation potential, as well as 
functional attributes of angiogenic cytokine (FGF, HGF, IL-8, TIMP-1, TIMP-2, and VEGF) secretion and 
inducible immunomodulatory potential (as measured by functional IDO activity), which are comparable to 2D 
control of similar PDL. Our development data supports the expansion of XF hMSCs in a scalable bioreactor 
culture platform, providing significant time and cost savings as a standardized system for translational 
researchers and product developers in the regenerative medicine, tissue engineering, and cell therapy fields.  
 
 
Figure 1 – Growth profiles of XF hBM-MSCs are comparable across various scales of microcarrier suspension 
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